Clinical trials: HER2-positive Circulating Tumor Cells
Breast Cancer
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00687648
- Testing
- anastrozole, cyclophosphamide, exemestane
- Where
- Singapore
- Volunteers
- 70 people
- Sponsor
- National Cancer Centre, Singapore
Neoplasms, Breast
Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
The underlying biology of the various patterns of metastasis observed in different tumour types remains unclear. The detection and characterization of circulating tumour cells in cancer patients has provided important new…
- Trial name
- NCT00820924
- Testing
- LAPATINIB
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Metastatic Breast Cancer
Trastuzumab and Vinorelbine in Advanced Breast Cancer
The purpose of this research study is to see what effects trastuzumab in combination with vinorelbine has on breast cancer when the participant has circulating tumor cells that are positive for the protein called HER2.
- Trial name
- NCT01185509
- Testing
- trastuzumab, vinorelbine
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms, HER2-positive Breast Cancer
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
Phase II unicentric randomized trial which will include early HER2 positive breast cancer patients, candidate to neoadjuvant therapy with trastuzumab and pertuzumab.
- Conditions
- Breast Neoplasms, HER2-positive Breast Cancer, Circulating Tumor Cell
- Trial name
- HER2Cell (NCT04993014)
- Testing
- Pertuzumab, Trastuzumab, Circulating tumor cells
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- AC Camargo Cancer Center
Breast Neoplasms
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with human epidermal growth factor receptor-2（HER-2）positive.
- Trial name
- NCT02510781
- Testing
- Epirubicin, Docetaxel, Trastuzumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hospital Affiliated to Military Medical Science, Beijing
Gastric Cancer Stage IV
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
BACKGROUND: Gastric cancer is one of the most common cancers and is one of the most deadly cancers. Most patients have advanced disease and should receive first-line trastuzumab-associated chemotherapy when the biopsy is positive…
- Trial name
- GASTHER2 (NCT04168931)
- Testing
- Trastuzumab
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- AC Camargo Cancer Center
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Patients with metastatic breast cancer considered HER2 negative are screened for HER2-amplified circulating tumor cells. If at least HER2-amplified circulating tumor cell is detected, patients are treated by Trastuzumab …
- Trial name
- NCT01975142
- Testing
- Trastuzumab - Emtansine
- Where
- 10 sites in France
- Volunteers
- 155 people
- Sponsor
- Institut Curie
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma
Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer
This clinical trial attempts to understand the differences between two chemotherapy drugs, ribociclib and palbociclib, and how they fight cancer.
- Conditions
- Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
- Trial name
- NCT05244434
- Testing
- Best Practice, Biopsy, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer…
- Conditions
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients
- Trial name
- NCT02035813
- Testing
- Ribociclib, Eribulin
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Prof. Wolfgang Janni
Breast Cancer
HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC
To evaluate the predictive and prognostic value of HER2 expression of circulating tumor cells in HER2-positive advanced breast cancer patients treated with ADC
- Trial name
- NCT05834686
- Testing
- HER2 expression of circulating tumor cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
The HER2 status in breast cancer patients may change during the course of the disease. In 30% of initially HER2-negative patients with circulating tumor cells (CTC), HER2-positive CTCs can be detected in peripheral blood…
- Trial name
- DETECT III (NCT01619111)
- Testing
- standard chemo- or endocrine therapy, standard chemo- or endocrine therapy + Lapatinib
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Prof. Wolfgang Janni
HER2-positive Metastatic Breast Cancer, Ovarian Cancer
Feasibility of a New Technology for Isolating Circulating Tumour Cells
This is a prospective interventional single-site research with a collection of biological samples. The primary objective of the trial is to assess the ability of the "new technology" to isolating circulating tumor cells (CTC) in…
- Conditions
- HER2-positive Metastatic Breast Cancer, Ovarian Cancer, Hormone-resistant Prostate Cancer, Circulating Tumor Cell
- Trial name
- CTC-SMMiL-E (NCT03979339)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Centre Oscar Lambret
HER2 Positive Advanced Gastric Cancer
HER2 Positive CTC in Advanced Gastric Cancer
To identify the correlation of HER2 expression in tissue and peripheral CTC. to identify the HER2 expression in CTCs with clinical prognosis in advanced/metastatic gastric cancer.
- Trial name
- AGC-HER2CTC (NCT01847794)
- Testing
- Cell Search® CTC epithelial kit
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University
Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
The purpose of this study is to look at the amount of cancer cells in the blood of participants who are being treated with denosumab.
- Conditions
- Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT03070002
- Testing
- Denosumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating tumour cells (CTC) in peripheral blood.
- Conditions
- Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells
- Trial name
- TREAT-CTC (NCT01548677)
- Testing
- trastuzumab
- Where
- 80 sites in Belgium, France and 2 more
- Volunteers
- 1,317 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC